Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $208M (up 8.2% year over year) with net income of $38M.
Q3 2026 key financials · XBRL
- Revenue
- $208M
- +8.2% YoY · +12.9% QoQ
- Net income
- $38M
- +117.7% YoY · +24.4% QoQ
- Operating margin
- 24.5%
- Gross margin
- 48.0%
- EPS (diluted)
- $0.86
- +132.4% YoY · +28.4% QoQ
Source: XBRL data from the Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 10-Q on SEC EDGAR. USD.
Amphastar Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $207.6M, up from $191.8M YoY, driven by BAQSIMI, Primatene MIST, and ipratropium bromide
- Gross profit $99.6M, margin 48.0% vs 51.4% YoY
- Best performer: BAQSIMI revenue $58.8M, up $5.2M; worst: glucagon $8.6M, down $5.0M, or 37%
- Nine-month operating cash flow $142.5M vs $123.3M; $100.0M BAQSIMI milestone payment and $75.1M treasury-stock purchases
- Outlook: glucagon sales expected to decline; IMS remediation may slow production and increase manufacturing expenses
Risk Factors
- IMS FDA warning letter, July 2, 2026, cited cGMP violations and triggered remediation efforts
- IMS product-release backlog approximately $12.5 million as of September 30, 2026
- IMS voluntarily suspended one product’s manufacture to prioritize products at shortage risk
- Insider-pledged shares expose stock price to forced-sale risk across 5.7 million pledged shares
- Credit lines totaled up to $57.0 million, including UBS’s unilateral call rights and lender acceleration rights
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amphastar Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.